Clinical trial
Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck…
NCT00024089 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00024089 |
|---|---|
| Title | Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer |
| Official title | A Phase II Study of ZD 1839 (Iressa) in Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | gefitinib |
| Enrollment | 60 |
| Start date | Jul 1, 2001 |
| Primary completion | Mar 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: